Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2025 | Aiming to optimize lymphodepletion strategies to enhance CAR-T efficacy

Lymphodepletion is a critical stage of the CAR T-cell therapy process; however, work remains to optimize lymphodepletion strategies. In this video, Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, comments on the importance of lymphodepletion and briefly highlights a project of the GoCART coalition that aims to put together a manuscript on lymphodepletion for special cohorts of patients, including frail and elderly individuals. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript (AI-generated)

The goal of the lymphodepletion regimen is to favor the expansion of CAR T-cells following infusion, in vivo expansion, which is probably a critical factor in the clinical efficacy of CAR T-cells. And although the number of regimens may look quite small and the number of drug combinations may look quite small, there are actually significant differences in doses and sequences in the administration of these treatments...

The goal of the lymphodepletion regimen is to favor the expansion of CAR T-cells following infusion, in vivo expansion, which is probably a critical factor in the clinical efficacy of CAR T-cells. And although the number of regimens may look quite small and the number of drug combinations may look quite small, there are actually significant differences in doses and sequences in the administration of these treatments. So understanding what is the optimal dose and the optimal association of these drugs is key, again the key factor in improving CAR T-cell efficiency, and obviously these drugs carry out some significant side effects. So the challenge is to frail people, elderly people, and this is what we are trying to look at in at least one of the GoCART supported projects.

 

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...